Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Ceapro Inc V.CZO

Ceapro Inc. is a Canada-based biotechnology company. The Company is involved in the development of extraction technology and the application of this technology to the production of extracts and active ingredients from oats and other renewable plant resources. Its primary business activities relate to the development and commercialization of natural products for personal care, cosmetic, human... see more

TSXV:CZO - Post Discussion

Ceapro Inc > Yeast beta glucan induces angiogenesis
View:
Post by prophetoffactz on May 23, 2024 8:28am

Yeast beta glucan induces angiogenesis

Angiogenesis is the formation of blood vessels through several stages. "...therapeutic angiogenesis is a process of inducing the growth of new blood vessels to improve blood flow to ischemic tissues. This approach has been studied to treat various diseases, including cardiovascular disease, peripheral artery disease, and wound healing". Our findings shows that angiogenesis proceeds through activation of PI3K/Akt/eNOS and ERK1/2 signaling pathway by particulate β-glucan induction. Yeast-derived particulate beta-glucan induced angiogenesis via regulating PI3K/Src and ERK1/2 signaling pathway - ScienceDirect
Comment by lscfa on May 23, 2024 8:53am
Please forward to CEO Gagnon and tell him to get on with it
Comment by prophetoffactz on May 23, 2024 8:59am
The Angiogenesis Foundation is extending studies on CZO's oat beta glucan for angiogenesis right now and talked about angiogensis when it discussed results to date previously.  The Foundation has played a pivotal role in developing over 43 FDA-approved angiogenesis-based therapies for cancer, wound healing, vision loss and other diseases. Yes, the Angiogenesis Foundation and its ...more  
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities